Adjuvant Chemotherapy For FIGO Stage IIA2 Cervical Cancer : A Case Report
Main Article Content
Abstract
Background : Cervical cancer ranked as the third most prevalent cancer among women. This case report is to examine the current status of adjuvant chemotherapy in the treatment of early-stage cervical cancer as documented in the literature. Currently, there is no established evidence supporting the therapeutic efficacy of adjuvant chemotherapy as a standalone treatment following radical hysterectomy surgery. Nevertheless, some literature recommend the use of adjuvant radiotherapy (AR), adjuvant chemotherapy (AC), or concomitant chemoradiotherapy (CCRT) as the standard adjuvant therapies for early-stage cervical cancer following radical hysterectomy with positive prognostic factor.
Case report: A 53-year-old female was diagnosed with stage IIA2 in April 2021. The histology type was determined to be keratinized squamous cell carcinoma, moderately well differentiated. The patient underwent a radical hysterectomy, resulting in the acquisition of uterine and cervical tissue measuring 11x11×6 cm. The histology results revealed moderately to poorly differentiated keratinizing squamous cell carcinoma, with no invasion of the parametrium or pelvic lymph nodes with vaginal cutting margin is free of tumor growth, but lymph vascular space invasion was present. Subsequently, adjuvant chemotherapy was administered using carboplatin (AUC 5) and paclitaxel for a total of 6 cycles. After 2 years with follow-up with CT-Scan examination in April 2023 confirmed the absence of any residual mass.
Conclusion: A radical hysterectomy combined with adjuvant chemotherapy has been shown to reduce the chance of recurrence or progressiveness of the disease, in which this patient did not experience a recurrence after two years of treatment
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright
Authors who publish with this journal agree to the following terms:
- Authors retain the copyright of published articles and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
License:
Andalas Obstetrics and Gynecology Journal (AOJ) is published under the terms of the Creative Commons Attribution 4.0 International License. This license permits anyone to copy and redistribute this material in any form or format, compose, modify, and make derivatives of this material for any purpose, including commercial purposes, as long as they credit the author for the original work.